Singh Jasvinder A, Dohm Michael, Choong Peter F
University of Alabama at Birmingham, Birmingham, AL, USA.
Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA.
BMC Musculoskelet Disord. 2017 Jan 26;18(1):45. doi: 10.1186/s12891-017-1409-4.
There are no core outcome domain or measurement sets for Total Joint Replacement (TJR) clinical trials. Our objective was to achieve an International consensus by orthopaedic surgeons on the OMERACT core domain/area set for TJR clinical trials.
We conducted surveys of two orthopaedic surgeon cohorts, which included (1) the leadership of international orthopaedic societies and surgeons (IOS; cohort 1), and (2) the members of the American Academy of Orthopaedic Surgeons' Outcome Special Interest Group (AAOS-Outcome SIG), and/or the Outcome Research Interest Group of the Orthopaedic Research Society (ORS; cohort 2). Participants rated OMERACT-endorsed preliminary core area set for TJR clinical trials on a 1 to 9 scale, indicating 1-3 as domain of limited importance, 4-6 being important, but not critical, and 7-9 being critical.
Eighteen survey participants from the IOS group and 69 participants from the AAOS-Outcome SIG/ORS groups completed the survey questionnaire. The median (interquartile range [IQR]) scores were seven or higher for all six proposed preliminary core areas/domains across both groups, IOS and AAOS-Outcome SIG/ORS, respectively: pain, 8 [8, 9] and 8 [7, 9]; function, 8 [8, 8] and 8 [7, 9]; patient satisfaction, 8 [7, 9] and 8 [7, 8]; revision surgery, 7 [6, 9] and 8 [6, 8]; adverse events, 7 [5, 8] and 7 [6, 9]; and death, 7 [7, 9] and 8 [5, 9]. Respective median scores were lower for two additional optional domains: patient participation, 6.5 [5, 7] and 6 [5, 8]; and cost, 6 [5, 7] and 6 [5, 7].
This study showed that two independent surveys dervied from three groups of orthopaedic surgeons with international representation endorsed a preliminary/draft OMERACT core domain/area set for Joint Replacement clinical trials.
全关节置换(TJR)临床试验尚无核心结局领域或测量集。我们的目标是就TJR临床试验的骨关节炎研究学会(OMERACT)核心领域/领域集达成骨科医生的国际共识。
我们对两组骨科医生进行了调查,其中包括(1)国际骨科协会和外科医生(IOS;队列1)的领导层,以及(2)美国骨科医师学会结局特别兴趣小组(AAOS-Outcome SIG)的成员,和/或骨科研究学会(ORS;队列2)的结局研究兴趣小组。参与者对OMERACT认可的TJR临床试验初步核心领域集进行1至9分的评分,表明1-3分为重要性有限的领域,4-6分为重要但不关键的领域,7-9分为关键领域。
IOS组的18名调查参与者和AAOS-Outcome SIG/ORS组的69名参与者完成了调查问卷。IOS组和AAOS-Outcome SIG/ORS组的所有六个提议的初步核心领域/领域的中位数(四分位间距[IQR])得分均为7或更高,分别为:疼痛,8[8,9]和8[7,9];功能,8[8,8]和8[7,9];患者满意度,8[7,9]和8[7,8];翻修手术,7[6,9]和8[6,8];不良事件,7[5,8]和7[6,9];以及死亡,7[7,9]和8[5,9]。另外两个可选领域的各自中位数得分较低:患者参与度,6.5[5,7]和6[5,8];以及成本,6[5,7]和6[5,7]。
本研究表明,来自三组具有国际代表性的骨科医生的两项独立调查认可了TJR临床试验的初步/草案OMERACT核心领域/领域集。